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Abstract 
 
Background: Dermatology Life Quality Index (DLQI) is the most common health-related 
quality of life measure in dermatology that is widely used in treatment guidelines for 
psoriasis. Eight out of the 10 questions of the DLQI offer a ‘not relevant’ response (NRR) 
option that is scored as the item had no impact on patients’ life at all. 
Objective: To explore the occurrence of NRRs on the DLQI in psoriasis patients, and to 
examine the effect of several socio-demographic and clinical factors on giving NRRs. 
Methods: Data were obtained from two cross-sectional surveys among psoriasis patients at 
two academic dermatology clinics in Hungary. Health-related quality of life was measured by 
employing DLQI and EQ-5D-3L, while disease severity was graded by Psoriasis Area and 
Severity Index (PASI). Multivariate logistic regression was applied to determine the 
predictors of providing NRRs. 
Results: Mean age of the 428 patients was 49 years, and 65% were males. Mean PASI, DLQI 
and EQ-5D-3L index scores were 8.4±9.5, 6.8±7.4 and 0.74±0.28, respectively. Overall, 
38.8% of the patients had at least one NRR: 19.6% (one), 11.5% (two), 5.1% (three) and 
2.6% (more than three). Most NRRs occurred in sport, sexual difficulties and 
working/studying items of the DLQI (28.4%, 16.4% and 14.0%, respectively). Female gender 
(OR 1.65; 95% CI 1.04-2.61), older age (OR 1.05; 95% CI 1.03-1.07) and higher PASI score 
(OR 1.03; 95% CI 1.01-1.06) were associated with providing more NRRs, whereas highly 
educated patients (OR 0.34; 95% CI 0.16-0.72) and those with a full-time job (OR 0.47; 95% 
CI 0.29-0.77) less frequently tended to tick NRRs.  
Conclusion: The high rate of psoriasis patients with NRRs, especially among women, less 
educated and elderly patients, indicates a content validity problem of the measure. A 
reconsideration of the use of the DLQI for medical and financial decision-making in psoriasis 
patients is suggested. 
 
Keywords: psoriasis, health-related quality of life, DLQI, medical decision-making, clinical 
guidelines 
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Introduction 
 
Dermatology Life Quality Index (DLQI) was the first, and to date, is the most commonly 
used health-related quality of life (HRQoL) measure in dermatological settings.
1-3
 Over the 
past two decades, it has pervaded the management of psoriasis patients in multiple ways. It 
serves as an easy-to-use instrument and a useful benchmark to evaluate treatment efficacy 
both in routine clinical work and in a variety of researches.
4
 It is by far the most commonly 
applied HRQoL tool in randomised controlled trials for interventions in psoriasis.
5
 According 
to the European consensus, DLQI is among the diagnostic criteria of moderate-to-severe 
psoriasis to determine which patients need to be offered systemic treatments.
6-8
 Furthermore, 
in many European countries, including the UK, Sweden, Denmark, Hungary, Poland, 
Romania and Croatia, DLQI is among reimbursement criteria for biological therapy alongside 
the Psoriasis Area and Severity Index (PASI).
9-11
  
The DLQI is a simple self-administered questionnaire that assesses the impact of a skin 
disease on HRQoL of the patient over the last week.
1
 The 10-item instrument includes the 
following six dimensions of HRQoL: symptoms and feelings, daily activities, leisure, work 
and school, personal relationships and treatment. Each question is scored on a four-point 
Likert-scale (‘not at all’=0, ‘a little’=1, ‘a lot’=2 and ‘very much’=3). Moreover, eight 
questions have ‘not relevant’ response (NRR) options that are given the same zero scores as 
‘not at all’ responses. Scores of individual items are added to yield a total score ranging from 
0 to 30, where a higher score represents a greater impairment of HRQoL. 
A NRR option in up to 80% of the questions of a HRQoL measure is rather unusual, 
especially in case of such a short questionnaire. Nevertheless, the literature regarding the 
occurrence of NRRs on the DLQI is scarce and inconsistent. The overwhelming majority of 
DLQI studies, including validation studies neglect to report the number of NRRs on the 
DLQI items or the proportion of patients with NRRs.
1,12-30
 On the other hand, studies from a 
variety of countries noted very high, others, on the contrary reported almost no NRRs in most 
questions of the DLQI.
31-38
 
Given that all NRRs are scored as 0 (equal to ‘not at all’ responses), they may artificially 
improve the DLQI score of patients who give at least one NRR in any item. The large number 
of NRRs may implicate a problem with the content validity of the DLQI. Despite the obvious 
anomaly in this answer option and its scoring, no study has provided a detailed analysis on 
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NRRs on the DLQI, so far. The objective of this study is thus to explore the occurrence of 
NRRs on the DLQI in a large sample of psoriasis patients, and to examine the effect of 
several socio-demographic and clinical factors on giving NRRs. 
 
Methods 
 
Study design 
Data from two cross-sectional questionnaire surveys among psoriasis patients aged 18 or 
above were combined. Detailed methodology of the studies has been published elsewhere.
39-
43
 Both surveys have been performed in a paper-based fashion at academic dermatology 
clinics in Hungary. The first study was carried out between September 2012 and May 2013 at 
two clinics: Semmelweis University, Department of Dermatology, Venereology and 
Dermatooncology (hereinafter referred as clinic #1) and at the University of Debrecen, 
Department of Dermatology (hereinafter referred as clinic #2). The survey involved 200 
consecutive outpatients with moderate-to-severe psoriasis. The second study, undertaken 
from September 2015 to June 2016 at clinic #1, enrolled 238 psoriasis patients regardless of 
disease severity. Consecutive outpatients, as well as patients hospitalized due to psoriasis 
were recruited to complete the questionnaire.  
Patient population 
A total of 438 psoriasis patients filled in the two questionnaire surveys. As clinic #1 
participated in both studies (99 patients in the first survey and 238 patients in the second 
survey), we tested whether an overlap would exist between the two patient populations. We 
identified four patients who completed both surveys; therefore, their data were included once 
(the later). Out of the 434 patients left after exclusion, further six patients were excluded, for 
whom a total DLQI score could not be calculated due to missing responses. Thus, the valid 
patient population for analysis consisted of 428 psoriasis patients. 
Outcome measures 
DLQI was applied to measure dermatology-specific HRQoL. A description of the DLQI and 
its scoring is provided in the Introduction. General health status and HRQoL was measured 
by the Hungarian version of the EQ-5D-3L (hereinafter referred as EQ-5D) questionnaire, 
which showed a good validity and responsiveness in psoriasis.
43-46
 It consists of two 
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measures, the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The 
descriptive system is based on the following five dimensions of HRQoL: mobility, self-care, 
usual activities, pain/discomfort and anxiety/depression. Patients may report no problems, 
some or moderate problems or extreme problems in each dimension, which results in a total 
of 3
5
=243 possible health states. In the lack of Hungarian national value set, EQ-5D index 
scores were calculated according to the UK one developed by Dolan,
47
 so values ranged 
between -0.594 and 1. The EQ VAS records the respondent’s self-rated health on a 20 cm 
vertical line, ranging from 0 (worst imaginable health state) to 100 (best imaginable health 
state). 
Disease severity was evaluated by PASI that grades the severity of psoriasis by the presence 
of erythema, induration and scaling and the extension of the lesions with respect to four body 
regions: head, trunk, upper and lower extremities.
48
 The PASI total score ranges from 0 to 72, 
where a higher score corresponds to a higher disease severity. 
Data analysis 
Descriptive statistics were computed for all socio-demographic and clinical variables as well 
as for HRQoL outcomes. Frequencies of responses in each DLQI item and mean DLQI 
scores were calculated. Patients were stratified into subgroups according to the banding 
DLQI system proposed by Hongbo et al. (DLQI scores 0-1 = no effect; DLQI scores 2-5 = 
small effect; DLQI scores 6-10 = moderate effect; DLQI scores 11-20 = very large effect; 
DLQI scores 21-30 = extremely large effect).
49
 Two different approaches were used to 
analyse the occurrence of NRRs on the DLQI. First, the proportion of NRRs was calculated 
for each item of the DLQI with the exception of the first and second, which offer no NRR 
options. Secondly, the total number of NRRs per patient was determined. This value was 
measured on a Likert-scale from 0 to 8.  
Due to skewed distribution of data, we applied Kruskal-Wallis test and Dunn-Bonferroni 
post-hoc test to compare DLQI, PASI, EQ-5D and EQ VAS scores between groups of 
patients classified according to their number of NRRs. Multivariate logistic regression was 
applied to determine predictors of providing NRRs. An odds ratio (OR) and its 95% 
confidence interval (CI) were calculated for each variable. The associations between gender 
and the number of NRRs along the DLQI items were analysed by Chi-square test. All the 
statistical tests were two-sided, and a p<0.05 was considered statistically significant. Data 
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were analysed by using IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM 
Corp. (2013). 
 
Results 
 
Characteristics of the patient population 
Mean age of the 428 psoriasis patients was 49.2±14.3 years (min. 18, max. 86 years), and 
65% were males (Table 1). Almost one-third of the patients had a college or university 
degree, and less than half of them worked in a full-time job. Similarly to the general 
population in Hungary higher rate of male patients worked (either full time or part time) in 
our sample, compared to females (62.6% vs. 44.7%, p<0.001). There was no significant 
difference among women and men concerning education (p=0.628). Mean disease duration 
was 19.9±12.3 years, and there were merely six patients who had been diagnosed less than a 
year before participating in the study. More than 80% of the patients presented with 
moderate-to-severe psoriasis. Mean PASI, DLQI, EQ-5D and EQ VAS scores of the total 
sample were 8.4±9.5, 6.8±7.4, 0.74±0.28 and 69.1±14.0, respectively. Distribution of patients 
according to DLQI bands is presented in Table 1. The majority of the patients were treated by 
biologics (43.7%), while 25% received systemic non-biological and 24.1% topical therapy 
only. There were 31 patients (7.2%) who received no medical treatment at the time of the 
survey. Most of them had a PASI score of over 10 and were right before the initiation of 
systemic therapy. 
 
Descriptive results of ‘not relevant’ responses 
Concerning items 6 (sport), 9 (sexual difficulties) and 7 (working or studying) 28.4%, 16.4% 
and 14% ticked a NRR, respectively (Table 2). In contrast, less than 3% of answers were 
NRRs in items 4 (clothes), 10 (treatment difficulties) and 5 (social activities). 
Out of the 428 patients, 166 (38.8%) gave at least one NRR on the DLQI. Of these, there 
were 84 patients (19.6%) with 1 NRR, 49 (11.5%) with 2 NRRs, 22 (5.1%) with 3 NRRs, 
seven (1.6%) with 4 NRRs, one (0.2%) with 5 NRRs, two (0.5%) with 6 NRRs, none with 7 
NRRs and one (0.2%) with 8 NRRs. Item 6 was ticked by the majority of patients with only 
one NRR (61.9%), followed by items 9 (20.2%) and 7 (15.5%). By increasing the number of 
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NRRs, the percentage of item 6 gradually decreases, while those of items 7, 8 and 9 clearly 
rise (Fig. 1).  
The proportion of NRRs per DLQI score bands is depicted in Fig. 2. Overall, 28% of patients 
with DLQI scores of 0 or 1 had at least one NRR. Corresponding percentages for patients 
with DLQI total scores of 2-5, 6-10 and 11-20 were 38%, 52% and 53%, respectively. The 
proportion of NRRs in patients with a DLQI ≥ 21 was 13%, on average.  
Determinants of ‘not relevant’ responses 
Mean DLQI scores of patients with 0, 1 and 2≤ NRRs were 6.5±8.0, 7.2±6.6 and 7.3±6.0, 
respectively (p=0.049). This trend, that patients with higher DLQI scores had more NRRs can 
be seen in Fig. 2 as well, with the exception of the group who had a result of more than 20 
points on the DLQI. Patients with 0, 1 and 2≤ NRRs showed mean PASI scores of 6.5±8.0, 
9.3±9.7 and 11.3±10.5, respectively (p<0.001). Worse general HRQoL (lower EQ-5D and 
EQ VAS scores) was also associated with a higher number of NRRs (p<0.001). Pairwise 
comparisons between groups confirmed these differences for PASI, EQ-5D and EQ VAS 
(Table 3). 
In a multivariate logistic regression, several socio-demographic and clinical characteristics 
were found to have a significant impact on NRRs (Table 4). Female gender was associated 
with a higher odds of providing NRRs (OR 1.646; 95% CI 1.039-2.608). Having a secondary 
school or a college/university degree decreased the odds of NRRs (OR 0.405; 95% CI 0.209-
0.784 and OR 0.343; 95% CI 0.164-0.717). Patients with full-time jobs less frequently had 
NRRs (OR 0.474; 95% CI 0.290-0.774). Besides these variables, older age (OR 1.049; 95% 
CI 1.031-1.068) and higher PASI score (OR 1.030; 95% CI 1.006-1.055) were related to an 
increased odds of the occurrence of NRRs. 
To identify which DLQI items are responsible for the difference between women and men, 
we compared responses of these two groups according to DLQI items (Table 5). The gender 
difference in providing NRRs was present in items 5 (social activities), 9 (sexual difficulties) 
and 10 (treatment difficulties) (p=0.008, p<0.001 and p=0.044, respectively). Items 6 (sport) 
and 8 (interpersonal problems) also demonstrated a trend towards significance (p=0.056 and 
p=0.058).  
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Discussion 
 
In the present study, we analysed the occurrence of NRRs on the DLQI in a large sample of 
psoriasis patients and revealed that DLQI total score, PASI and several socio-demographic 
factors affected the number of NRRs given by a patient. We believe that our study provides 
three major findings. 
First, 38.8% of psoriasis patients provided at least one NRR. Furthermore, more patients with 
DLQI scores of 6 to 20 had at least one NRR than those who did not. This suggests that 
certain items of the DLQI are not important for a significant number of psoriasis patients. 
Secondly, as NRRs are scored as being 0, higher number of NRRs is expected to yield a 
lower DLQI total score. Yet evidence from our study testifies the contrary; the higher the 
DLQI score, the more NRRs are ticked (Fig.2). The high rate of psoriasis patients with NRRs 
and the unexpected inverse association between DLQI score and the number of NRRs 
indicates a content validity problem of the measure. This is supported by the fact that patients 
with more NRRs had more severe psoriasis (i.e. higher PASI scores). By eliminating DLQI 
items that were answered NRRs in the calculation of the total score and then converting these 
raw scores to scores on a 0 to 30 scale, the mean total DLQI score of the 166 patients with 
NRRs in our sample would increase from 7.23 to 8.94 (p<0.001). The rise in DLQI score is 
more prominent in the age group of >65 years (n=46), whose mean DLQI total score would 
rise from 7.41 to 10.15 points (p<0.001). Thirdly, we observed that some socio-demographic 
groups tended to provide more NRRs. In our study, these groups were elderly, females, those 
not working full-time and less educated patients. The gender difference is particularly 
important considering the fact that in large European registries, a higher proportion of men 
with psoriasis are treated with systemic therapy.
11,50
 Nevertheless, more studies with larger 
sample sizes are required to confirm the generalisability of these findings.  
In consistent with the literature, NRRs were the most common in the items of sport, sexual 
difficulties and working or studying.
31-34,36-38
 It appears that these items are more often not 
relevant to elderly psoriasis patients compared with their younger peers. Nevertheless, 
psoriasis is a life-long condition and a HRQoL instrument should be relevant for every 
patient regardless of age. This is becoming more important with the increasingly aging 
population in the developed countries.  
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A further, very important problem about items 6 (sports) and 9 (sexual difficulties) is that the 
DLQI assesses the impact of a skin disease on HRQoL of the patient over the last week. On 
the one hand, there are many arguments in favour of applying a one-week time frame; for 
example, the shorter recall period can be more sensitive to recent changes in health status or 
less recall bias may occur.
51
 On the other hand, many people, also among members of the 
general population, are not involved in these activities on a weekly basis. Thus, if the DLQI 
covered a longer time span, items 6 and 9 would be more likely relevant for a higher 
proportion of patients, and they might report a problem in these items, too.  
Limitations of the current study include the following. First, despite the large sample size, 
less than 10 NRRs were reported in some items of the DLQI and only a few patients reported 
more than two NRRs. However, a heterogeneous psoriasis patient population was recruited 
both in terms of socio-demographic and clinical characteristics, which was excellent for the 
purposes of the study. Secondly, some authors have addressed that patients may 
misunderstand the term ‘not relevant’ and cannot judge between ‘not at all’.31,32 We have no 
data regarding how many patients were not able to make a clear difference between the NRR 
and the ‘not at all’ answer options on the DLQI. For example, none of the 31 patients who 
were not treated at the time of the survey provided a NRR on item 10 (treatment), or out of 
the 19 unemployed patients in our study, six marked any NRR in the questionnaire, only one 
of which occurred in the working/studying item. Based on these, the actual rate of NRRs 
could be overestimated or even underestimated in the current study. The term ‘not relevant’ is 
translated differently in other language versions of the DLQI, which may, in part, explain the 
variances in the rates of NRRs across countries [e.g. German: ‘betrifft mich nicht’ (=it does 
not concern me), Hungarian: ‘nem vonatkozik Önre’ (=it is not relevant for you), Italian: 
‘Non riguarda il mio caso’ (=It does not affect my case), Swedish – ‘Ej tillämpligt’ (=Not 
applicable)].
52
 This draws the attention to the presence of systematic measurement bias in 
multi-country studies in which the DLQI is filled in by patients with different languages.  
At the time the DLQI was developed in the early 1990s, the aim of HRQoL assessment was 
to quantify the quality of life loss experienced by patients. Being the first dermatology-
specific HRQoL measure, it brought a paradigm shift in dermatological care, and its merits 
should not be overlooked.
53
 In the context of the present paper, NRRs may be useful, for 
example, to identify patients who are unemployed or do not go in for sport. Yet very few 
studies reported on the number of NRRs and exploited this additional information provided 
by the DLQI.
31-38
 Over the past two decades, owing to advances in therapy such as biological 
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drugs, the DLQI has become a reference point for not only medical but financial decision-
making. Currently, the DLQI is widely used in diagnostic criteria for moderate-to-severe 
psoriasis – (body surface area >10 or PASI>10) and DLQI>10 – and for reimbursement 
decision-making regarding biologics.
7-10,54
  
There is, however, a growing body of literature questioning the feasibility and pointing out 
the inherent limitations of the DLQI as a HRQoL measure. In previous studies, Rasch 
analysis and factor analysis could not confirm its unidimensionality (i.e. that all items in the 
scale underlie the same construct) and detected that certain DLQI items are affected by 
external factors, such as age, gender and cultural background of patients.
16,20,34,55-59
 Another 
study found discrepancies between DLQI scores and time trade-off utility values, suggesting 
that HRQoL in two patients with identical DLQI scores might be significantly different, 
while patients whose DLQI scores differ larger than the minimal clinically important 
difference may be equal.
60,61
 Considering the number of jurisdictions, in which the DLQI is 
used in national guidelines, including the European S3-Guidelines on the systemic treatment 
of psoriasis vulgaris,
7-11,62-66
 the amount of patients affected worldwide may be very large. 
Our results, taken together with other findings in the literature, suggest that the applicability 
of the DLQI in the management of psoriasis patients may be called into question.  
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Figure legends 
 
Figure 1 Distribution of DLQI items according to the number of ‘not relevant’ 
responses per patient* 
*There is no ’not relevant’ option in the first and second item of the DLQI. 
 
Figure 2 Number of ‘not relevant’ responses by DLQI score bands 
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Tables 
Table 1 Characteristics of the psoriasis patient population (N=428) 
Variables Mean (SD) or N (%) 
Gender 
 Female 150 (35.0%) 
Male 278 (65.0%) 
Age (years) 49.2 (14.3) 
Disease duration (years) 19.9 (12.3) 
Education  
Primary school 58 (13.6%) 
Secondary school 243 (56.8%) 
College/university 127 (29.7%) 
Employment**  
Student 10 (2.3%) 
Full-time  207 (48.4%) 
Part-time 35 (8.2%) 
Unemployed 19 (4.4%) 
Retired 84 (19.6%) 
Disability pensioner 60 (14.0%) 
Other 26 (6.1%) 
EQ-5D-3L (-0.594-1) (missing=5) 0.74 (0.28) 
EQ VAS (0-100) 69.1 (14.0) 
DLQI (0-30) 6.8 (7.4) 
0-1 148 (34.6%) 
2-5 95 (22.2%) 
6-10 71 (16.6%) 
11-20 90 (21.0%) 
21-30 24 (5.6%) 
Disease severity  
PASI (0-72) 8.4 (9.5) 
Mild psoriasis 80 (18.7%) 
Moderate-to-severe psoriasis* 348 (81.3%) 
Clinical subtype**  
Chronic plaque psoriasis 314 (73.4%) 
Guttate 27 (6.3%) 
Erythrodermic 7 (1.6%) 
Facial and/or inverse 78 (18.2%) 
Scalp 205 (47.9%) 
Palmoplantar 26 (6.8%) 
Nail 194 (45.3%) 
Psoriatic arthritis 154 (36.0%) 
Pustular 2 (0.5%) 
Treatments  
None 31 (7.2%) 
Topical only 103 (24.1%) 
Systemic non-biologic 107 (25.0%) 
Biologic 187 (43.7%) 
* Patients were considered moderate-to-severe if met the criteria of body surface area > 10 or PASI > 10 and 
DLQI > 10 
6,7
 or if they were treated by systemic therapy either non-biological or biological at the time of the 
survey. 
**Combinations may occur. 
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DLQI= Dermatology Life Quality Index; PASI = Psoriasis Area and Severity Index; VAS = visual analogue 
scale 
 
Table 2 Distribution of responses on the 10 items of the DLQI 
DLQI items N Not relevant Not at all A little A lot Very much  
Item 1 (sore, itchy, painful) 428 N/A 157 (36.7%) 124 (29.0%) 87 (20.3%) 60 (14.0%) 
Item 2 (embarrassment) 428 N/A 202 (47.2%) 102 (23.8%) 69 (16.1%) 55 (12.9%) 
Item 3 (shopping/home) 427 7 (1.6%) 282 (66.0%) 75 (17.5%) 49 (11.5%) 14 (3.3%) 
Item 4 (clothes) 428 3 (0.7%) 232 (54.2%) 75 (17.5%) 62 (14.5%) 56 (13.1%) 
Item 5 (social activities) 428 11 (2.6%) 238 (55.6%) 80 (18.7%) 55 (12.9%) 44 (10.3%) 
Item 6 (sport) 426 121 (28.4%) 200 (46.9%) 45 (10.6%) 31 (7.3%) 29 (6.8%) 
Item 7 (working/studying) 428 60 (14.0%) 256 (59.8%) 61 (14.3%) 26 (6.1%) 25 (5.8%) 
Item 8 (interpersonal problems) 428 20 (4.7%) 260 (60.7%) 83 (19.4%) 48 (11.2%) 17 (4.0%) 
Item 9 (sexual difficulties) 428 70 (16.4%) 274 (64.0%) 44 (10.3%) 23 (5.4%) 17 (4.0%) 
Item 10 (treatment difficulties) 428 9 (2.1%) 201 (47.0%) 113 (26.4%) 66 (15.4%) 39 (9.1%) 
N/A=not applicable 
DLQI= Dermatology Life Quality Index 
 
Table 3 Associations between DLQI, PASI, EQ-5D and EQ VAS and the number of ‘not 
relevant’ responses on the DLQI 
 
Number of ‘not 
relevant’ 
responses 
N (%) 
Mean (SD) 
DLQI (0-30) PASI (0-72) 
EQ-5D-3L  
(-0.594 to 1) 
EQ VAS  
(0-100) 
0 262 (61.2%) 6.5 (8.0) 7.1 (3.5) 0.79 (0.25) 71.8 (19.9) 
1 84 (19.6%) 7.2 (6.6) 9.3 (9.7) 0.71 (0.29) 68.2 (22.2) 
 ≥2 82 (19.2%) 7.3 (6.0) 11.3 (10.5) 0.60 (0.32) 61.5 (21.7) 
Multivariate p-value* 0.049 <0.001 <0.001 <0.001 
Pairwise p-
value** 
0 vs. 1 0.240 0.064 0.023 0.714 
0 vs. ≥2 0.111 0.000 0.000 0.000 
1 vs. ≥2 1.000 0.358 0.053 0.085 
*Kruskal-Wallis test, where p<0.05 was considered statistically significant. 
** Dunn-Bonferroni post-hoc test, where p<0.05 was considered statistically significant. 
On DLQI and PASI, higher scores refer to a worse health state, while on EQ-5D and EQ VAS, higher scores 
correspond to a better health state. 
DLQI= Dermatology Life Quality Index; PASI = Psoriasis Area and Severity Index 
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Table 4 Multivariate logistic regression on providing at least one ‘not relevant’ response 
on the DLQI  
 Regression coefficient (β) SE OR (95% CI) p-value 
Constant -1.668 0.599 0.189 0.005 
Gender (female) 0.498 0.235 1.646 (1.039-2.608) 0.034 
Age 0.048 0.009 1.049 (1.031-1.068) 0.000 
PASI score 0.030 0.012 1.030 (1.006-1.055) 0.014 
Education     
Secondary school -0.905 0.337 0.405 (0.209-0.784) 0.007 
College/university -1.071 0.377 0.343 (0.164-0.717) 0.004 
Full-time job -0.746 0.250 0.474 (0.290-0.774) 0.003 
Note:  n=428, dependent variable: zero ‘not relevant’ responses = 0; ≥1 ‘not relevant’ response =1, Nagelkerke 
R
2
=0.286. 
SE= standard error; OR = odds ratio; CI= confidence interval 
 
 
 
Table 5 Association between gender and frequencies of ‘not relevant’ responses per item 
DLQI items 
‘Not relevant’ responses (N, %) 
p-value* Male 
(N=278) 
Female (N=150) 
Item 1 (sore, itchy, painful) N/A N/A - 
Item 2 (embarrassment) N/A N/A - 
Item 3 (shopping/home) 6 (2.2%) 1 (0.7%) 0.244 
Item 4 (clothes) 1 (0.4%) 2 (1.3%) 0.252 
Item 5 (social activities) 3 (1.1%) 8 (5.3%) 0.008 
Item 6 (sport) 70 (25.3%) 51 (34.0%) 0.056 
Item 7 (working/studying) 35 (12.6%) 25 (16.6%) 0.258 
Item 8 (interpersonal problems) 9 (3.2%) 11 (7.3%) 0.058 
Item 9 (sexual difficulties) 31 (11.2%) 39 (26.0%) <0.001 
Item 10 (treatment difficulties) 3 (1.1%) 6 (4.0%) 0.044 
Total  93 (33.5%) 73 (48.7%) 0.002 
N/A=not applicable 
DLQI= Dermatology Life Quality Index 
*Chi-square test, where a p-value of <0.05 was considered statistically significant. 
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